#wolfe-research
Latest news and interesting information about wolfe-research.
Wolfe Research Downgrades Boston Scientific
Wolfe Research downgraded Boston Scientific to Peer Perform as PFA and Watchman growth falter. Analyst sees 7% growth in 2027, stock in low $50s.
Wolfe Research Reaffirms Ionis Stock Outperform Rating
Wolfe Research reiterates Outperform rating on Ionis Pharmaceuticals stock. Analysis of Arrowhead competition and financial results.
Wolfe Research Starts Alto Neuroscience with Outperform
Wolfe Research initiates coverage on Alto Neuroscience with an outperform rating and $35 price target. ALTO-207 pipeline highlighted.
Wolfe Research Cuts Lowe's Price Target on Weak Demand
Wolfe Research lowers Lowe's price target to $254 on muted demand outlook, maintaining Outperform rating.
Wolfe Research Initiates CytomX Stock with Outperform
Wolfe Research initiated CytomX Therapeutics (CTMX) with an outperform rating and $3.50 target. Varseta-M shows promise in colorectal cancer.
Wolfe Research initiates Mirum with outperform
Wolfe Research starts Mirum Pharmaceuticals with outperform rating and $145 price target, citing strong pipeline potential.
Wolfe Research Initiates Oklo with Peerperform
Wolfe Research initiated Oklo Inc. with a Peerperform rating. Learn about the company's targets, finances, and stock performance.
Wolfe Research Boosts AMAT Target to $550
Wolfe Research raised Applied Materials price target to $550 from $500, citing strong guidance and revenue growth. Shares have gained 154% in the past year.
Wolfe Research Reiterates Peerperform on Cisco
Wolfe Research reiterates Peerperform on Cisco stock. Detailed analysis of Cisco's quarterly results and outlook.
...